Scholarlink

Background <p>Immunotherapy (IO) re-challenge for cancer patients has sparked widespread discussion and attention in recent years. The optimal second-line treatment strategies for patients with metastatic esophageal squamous cell carcinoma (ESCC) after first-line IO failure remains to be further explored. This study aimed to compare the real-world safety and efficacy of IO re-challenge combined with chemoradiotherapy (CRT) versus CRT alone in metastatic ESCC patients.</p> Methods <p>We conducted a real-world retrospective study on 59 patients with ESCC who received second-line therapy after first-line IO failure at the Cancer Center of Renmin Hospital of Wuhan University from September 2019 to December 2023. Patients were divided into the IO plus CRT group (<i>n</i> = 34) and CRT alone group (<i>n</i> = 25). Clinical efficacy and adverse events (AEs) were analyzed and compared. Primary outcomes included median overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and safety. Subgroup analysis was also performed.</p> Results <p>Compared with the CRT alone, IO re-challenge combined with CRT showed significantly improved median OS (11.4 months vs. 6.2 months; adjusted HR = 0.48; 95% <i>CI</i>: 0.25–0.90; <i>P</i> = 0.022), PFS (6.8 months vs. 3.9 months; adjusted HR = 0.50; 95% CI: 0.27–0.94; <i>P</i> = 0.031), and higher ORR (35.3% vs. 16.0%) and DCR (88.2% vs. 68.0%). Patients with the following characteristics: male, stage III-IV, primary tumor located in the middle esophagus, with regional lymph node metastasis and/or distant metastasis, and first-line PFS &gt; 6 months were more likely to obtain OS benefit from IO re-challenge combined with CRT. The incidence of grade ≥ 3 AEs in the two groups of patients were 44.1% and 40.0%, respectively, and mainly including leukopenia, neutropenia, anemia, thrombocytopenia, fatigue and loss of appetite.</p> Conclusions <p>Second-line IO re-challenge combined with CRT provided significant survival benefits and controllable safety compared with CRT alone for ESCC patients who had disease progression after first-line IO failure. Further prospective study is needed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparing immunotherapy re-challenge plus chemoradiotherapy versus chemoradiotherapy alone in metastatic esophageal squamous cell carcinoma after first-line immunotherapy failure

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月7日

查看全文
  • Jian Song,
  • Jie Shu,
  • Wensi Zhao

摘要

Background

Immunotherapy (IO) re-challenge for cancer patients has sparked widespread discussion and attention in recent years. The optimal second-line treatment strategies for patients with metastatic esophageal squamous cell carcinoma (ESCC) after first-line IO failure remains to be further explored. This study aimed to compare the real-world safety and efficacy of IO re-challenge combined with chemoradiotherapy (CRT) versus CRT alone in metastatic ESCC patients.

Methods

We conducted a real-world retrospective study on 59 patients with ESCC who received second-line therapy after first-line IO failure at the Cancer Center of Renmin Hospital of Wuhan University from September 2019 to December 2023. Patients were divided into the IO plus CRT group (n = 34) and CRT alone group (n = 25). Clinical efficacy and adverse events (AEs) were analyzed and compared. Primary outcomes included median overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and safety. Subgroup analysis was also performed.

Results

Compared with the CRT alone, IO re-challenge combined with CRT showed significantly improved median OS (11.4 months vs. 6.2 months; adjusted HR = 0.48; 95% CI: 0.25–0.90; P = 0.022), PFS (6.8 months vs. 3.9 months; adjusted HR = 0.50; 95% CI: 0.27–0.94; P = 0.031), and higher ORR (35.3% vs. 16.0%) and DCR (88.2% vs. 68.0%). Patients with the following characteristics: male, stage III-IV, primary tumor located in the middle esophagus, with regional lymph node metastasis and/or distant metastasis, and first-line PFS > 6 months were more likely to obtain OS benefit from IO re-challenge combined with CRT. The incidence of grade ≥ 3 AEs in the two groups of patients were 44.1% and 40.0%, respectively, and mainly including leukopenia, neutropenia, anemia, thrombocytopenia, fatigue and loss of appetite.

Conclusions

Second-line IO re-challenge combined with CRT provided significant survival benefits and controllable safety compared with CRT alone for ESCC patients who had disease progression after first-line IO failure. Further prospective study is needed.